ArticleInternational ophthalmology2026
Risk factors for posterior capsule opacification following phacovitrectomy: a six-year retrospective analysis.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo study risk factors for Nd:YAG capsulotomy (YAG-CT) due to visually disturbing posterior capsule opacification (PCO) after combined cataract surgery and vitrectomy, phaco-vitrectomy (PhV).
methodsSingle-center retrospective comparative cohort study. We included 196 patients (197 eyes) undergoing PhV. Electronic medical records provided baseline patient data, data on indication for vitrectomy, surgery data including intra-ocular lens (IOL) type, complications, and YAG-CT incidence during 6-year follow-up after PhV. Univariate and multivariate regression analyses assessed associations of various factors with YAG-CT incidence.
resultsFifty-four eyes (27.41%) underwent YAG-CT during the follow-up period. One of the three hydrophilic acrylic IOLs showed the lowest YAG-CT incidence. Adjusted Odds Ratios (aORs) for YAG-CT were significantly higher for the hydrophobic acrylic IOL (aOR = 5.85, p < .05), and the two other hydrophilic acrylic IOLs (aOR = 29.0, p < 0.001 and aOR = 79.4, p < 0.001). Compared with PhV for macular hole, PhV for epiretinal membranes (aOR = 9.9, p < 0.01), retinal detachment (aOR = 25.4, p < 0.01), and silicon oil removal (aOR = 22.4, p < 0.05) correlated with higher YAG-CT incidence. Type 2 diabetes correlated with increased YAG-CT incidence (aOR = 6.7, p < 0.01).
conclusionIOL type is a key factor in development of visually disturbing PCO after phacovitrectomy. One hydrophilic acrylic IOL outperformed other examined IOLs in reducing YAG-CT incidence after PhV. Retinal disease, as well as type 2 diabetes, correlated with YAG-CT, and should motivate a choice of an IOL type associated with a low YAG-CT incidence for PhV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.